Plain-English translation of NCT06463834 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two treatments— (an immunotherapy that helps your immune system fight cancer) plus standard chemotherapy—given before surgery for esophageal squamous cell carcinoma. The goal is to shrink the tumor as much as possible before the surgeon removes it, which may improve your chances of a complete recovery.
Currently, people with this type of esophageal cancer receive chemotherapy before surgery, but outcomes could be better. Researchers believe adding this immunotherapy medication to chemotherapy might help more patients achieve a complete disappearance of cancer cells before surgery, potentially improving survival and quality of life.
You likely qualify if…
You likely don't qualify if…
You would receive three cycles of the medication combination ( plus chemotherapy), typically given over several weeks as an outpatient. Each cycle involves receiving the drugs through an IV, followed by recovery time. After completing all three cycles, you would have imaging scans to see how well the treatment worked, and then you would proceed to surgery to remove the tumor. The entire treatment phase before surgery usually takes about 6–9 weeks.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fujian Cancer Hospital
Enrollment target
~30 participants
Started
March 2024
Primary completion
March 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shuoyan Liu
Fujian Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.